Keyboard IconSay and Search
Full Text
PDF
Antimicrobial Agents and Chemotherapy

Ceftazidime-Avibactam Activity against Multidrug-Resistant Pseudomonas aeruginosa Isolated in U.S. Medical Centers in 2012 and 2013

star_border
     Loading your article ...      Welcome to Your Next Discovery   
PDF
Article Details
Authors
Helio S. Sader, Mariana Castanheira, Rodrigo E. Mendes, Robert K. Flamm, David J. Farrell, Ronald N. Jones
Journal
Antimicrobial Agents and Chemotherapy
Date
05024
DOI
10.1128/aac.05024-14
Table of Contents
Abstract
Ceftazidime-Avibactam Activity Against Multidrug-Resistant
Helio S. Sader, Mariana Castanheira, Rodrigo E. Mendes, Robert K. Flamm, David J. Farrell, Ronald N. Jones
JMI Laboratories, North Liberty, Iowa, USA
81.9, And 78.5%, Respectively. Multidrug-Resistant And Extensively Drug-Resistant Phenotypes Were Observed In 14.9 And 8.7% Of The Strains, Respectively, And 81.0 And 73.7% Of The Strains Were Susceptible To Ceftazidime-Avibactam, Respectively.
ACKNOWLEDGMENTS
Abstract
Pseudomonas aeruginosa isolates (n 3,902) from 75 U.S. medical centers were tested against ceftazidime-avibactam and comparator agents by the reference broth microdilution method. Overall, 96.9% of the strains were susceptible (MIC, <8 g/ml) to ceftazidime-avibactam, while the rates of susceptibility for ceftazidime, meropenem, and piperacillin-tazobactam were 83.8, 81.9, and 78.5%, respectively. Multidrug-resistant and extensively drug-resistant phenotypes were observed in 14.9 and 8.7% of the strains, respectively, and 81.0 and 73.7% of the strains were susceptible to ceftazidime-avibactam, respectively.
Ceftazidime-Avibactam Activity against Multidrug-Resistant
Pseudomonas aeruginosa Isolated in U.S. Medical Centers in 2012 and 2013
Helio S. Sader, Mariana Castanheira, Rodrigo E. Mendes, Robert K. Flamm, David J. Farrell, Ronald N. Jones
JMI Laboratories, North Liberty, Iowa, USA
Pseudomonas aeruginosa isolates (n 3,902) from 75 U.S. medical centers were tested against ceftazidime-avibactam and comparator agents by the reference broth microdilution method. Overall, 96.9% of the strains were susceptible (MIC, <8 g/ml) to ceftazidime-avibactam, while the rates of susceptibility for ceftazidime, meropenem, and piperacillin-tazobactam were 83.8,
81.9, and 78.5%, respectively. Multidrug-resistant and extensively drug-resistant phenotypes were observed in 14.9 and 8.7% of the strains, respectively, and 81.0 and 73.7% of the strains were susceptible to ceftazidime-avibactam, respectively.
Pseudomonas aeruginosa causes a wide range of serious clinicalinfections, including hospital-acquired pneumonia, ventilator-associated pneumonia (VAP), bacteremia, skin and skin structure infections, and urinary tract infections (UTI). Data from the Healthcare Safety Network indicate that P. aeruginosa was responsible for 7.5% of all health care-associated infections from 2009 to 2010 (1). When stratified by type of infection, P. aeruginosa was responsible for 16.6% of VAP (second only to Staphylococcus aureus), 11.3% of catheter-related UTI, 5.5% of surgical site infections, and 3.8% of central line-associated bloodstream infections. P. aeruginosa presents a serious therapeutic challenge because it exhibits intrinsically decreased susceptibility to a range of antimicrobials and possesses a great ability to develop resistance to multiple classes of agents (2, 3). P. aeruginosa carries an inducible AmpC cephalosporinase, which is similar to the chromosomally encoded AmpC found in Enterobacteriaceae, and when AmpC production is significantly increased, P. aeruginosa exhibits resistance to all -lactams currently available for clinical use, with the exception of the carbapenems (3). Furthermore, upregulation of MexA-MexB-OprM and the loss of OprD are considered the most prevalent mechanisms of carbapenem resistance in P. aeruginosa, and these mechanisms are usually associated with AmpC hyperproduction (2, 4–6). Avibactam is a member of a novel class of non- -lactam -lactamase inhibitors, the diazabicyclooctanes (DBOs) (7). Compared to the inhibitors currently available for clinical use, DBOs are more potent and have a broader spectrum and different mechanism of action. Avibactam effectively inactivates class A (including Klebsiella pneumoniae carbapenemase [KPC]), class C (AmpC), and some class D (OXA) -lactamases, with low 50% inhibitory concentration (IC50) values and low turnover numbers. Thus, avibactam extends the antibacterial activity of ceftazidime against most ceftazidime-resistant organisms that produce those cited enzymes, including P. aeruginosa (8–10). Ceftazidimeavibactam is approved by the U.S. Food and Drug Administration (FDA) for the treatment of complicated intra-abdominal and complicated urinary tract infections (11). In this study, we evaluated the activity of ceftazidime combined with avibactam when tested against a large collection of contemporary P. aeruginosa clinical isolates recovered in U.S. medical centers in 2012 and 2013. A total of 3,902 P. aeruginosa isolates were collected from 75 U.S. hospitals from January 2012 to December 2013 as part of the International Network for Optimal Resistance Monitoring (INFORM) program. The participant medical centers were distributed among 31 states from all nine U.S. Census regions, with one to four medical centers per state (6 to 14 centers by Census regions), and the majority of the medical centers were large tertiary hospitals. These isolates were collected from patients hospitalized with pneumonia (46.6%), skin and soft tissue infections (26.9%), bloodstream infections (7.5%), urinary tract infections (7.9%), intra-abdominal infections (3.7%), and other infection types (7.5%), according to defined protocols (10). Only clinically significant isolates were included in the study (one per patient episode). Species identification was confirmed when necessary by matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) using the Bruker Daltonics MALDI Biotyper (Billerica, MA, USA), according to the manufacturer’s instructions. All isolates were tested for susceptibility using the reference broth microdilution method, as described by the Clinical and Laboratory Standards Institute (CLSI) (12). Ceftazidime was combined with avibactam at a fixed concentration of 4 g/ml, as described in the ceftazidime-avibactam package insert (11). The combination of ceftazidime plus a constant 4 g/ml avibactam was chosen for susceptibility testing over the alternatives and standardized by CLSI and the European Committee for Antimicrobial Received 11 December 2014 Returned for modification 14 March 2015 Accepted 29 March 2015 Accepted manuscript posted online 6 April 2015 Citation Sader HS, Castanheira M, Mendes RE, Flamm RK, Farrell DJ, Jones RN. 2015. Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013. Antimicrob Agents Chemother 59:3656 –3659. doi:10.1128/AAC.05024-14. Address correspondence to Helio S. Sader, helio-sader@jmilabs.com. Copyright © 2015, American Society for Microbiology. All Rights Reserved. doi:10.1128/AAC.05024-14 3656 aac.asm.org June 2015 Volume 59 Number 6Antimicrobial Agents and Chemotherapy on M ay 28, 2015 by P E N N S T A T E U N IV http://aac.asm .org/ D ow nloaded from Susceptibility Testing (EUCAST), based on the pharmacokinetic characteristics of avibactam and the ability of this combination to separate isolates that have been predefined as susceptible or resistant based on the -lactamases expressed and the known -lactamase inhibition profile of avibactam (13, 14). Categorical interpretations for all antimicrobials were those found in CLSI document M100-S24 (15) and EUCAST (16) breakpoint tables. U.S. FDA breakpoint criteria were applied for ceftazidime-avibactam (11). To better evaluate ceftazidimeavibactam activity against resistant subsets of P. aeruginosa, the strains were stratified by their susceptibility patterns to ceftazidime, meropenem, and piperacillin-tazobactam. Multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacteria were classified per recently recommended guidelines (17), using the following antimicrobial class representative agents and CLSI interpretive criteria (15): ceftazidime, 16 g/ml; meropenem, 4 g/ml; piperacillin-tazobactam, 32 g/ml; levofloxacin, 4 g/ ml; gentamicin, 8 g/ml; and colistin, 4 g/ml. Classifications were based on the following recommended resistance parameters: MDR, nonsusceptible to 1 agent in 3 antimicrobial classes; XDR, nonsusceptible to 1 agent in all but 2 antimicrobial classes (17). Quality control (QC) was performed using Escherichia coli strain ATCC 25922 and P. aeruginosa strain ATCC 27853. All QC results were within acceptable ranges, as published in recent CLSI documents (15). Ceftazidime-avibactam (MIC50/90, 2/4 g/ml; 96.9% susceptible at 8 g/ml [11]; Table 1) exhibited greater in vitro activity than ceftazidime tested alone (MIC50/90, 2/32 g/ml; 83.8% susceptible at 8 g/ml; Table 2) when processed against the entire collection of P. aeruginosa. The overall susceptibility (by CLSI criteria, Table 2) rates for cefepime (83.6%) and meropenem (81.9%) were similar to that of ceftazidime (83.8%) and lower than that of ceftazidime-avibactam, at 8 g/ml (96.9%). Piperacillin-tazobactam (MIC50/90, 8/ 64 g/ml) inhibited 78.5% of the strains at the CLSI susceptible breakpoint of 16 g/ml, and 74.9 and 88.9% of strains were susceptible (CLSI) to levofloxacin and gentamicin, respectively (Table 2). Among the comparator agents, amikacin (MIC50/90, 2/8 g/ml; 97.4% susceptible at 16 g/ml, per the CLSI criteria) and colistin (MIC50/90, 1/2 g/ml; 99.3% susceptible at 2 g/ml, per the CLSI criteria]) were the most active compounds (Table 2). Ceftazidime-avibactam inhibited 80.9% of the ceftazidimenonsusceptible P. aeruginosa isolates (ceftazidime MIC, 16 g/ ml; 634 isolates tested) at 8 g/ml (Table 1). Ceftazidime- avibactam also showed potent activity against meropenemnonsusceptible P. aeruginosa (meropenem MIC, 4 g/ml; 702 isolates tested), inhibiting 86.5% of the strains at 8 g/ml (Table 1). The most active antimicrobials tested against meropenem-nonsusceptible P. aeruginosa were ceftazidime-avibactam (MIC50/90, 4/16 g/ml; 86.5% susceptible; Table 1), amikacin (MIC50/90, 4/16 g/ml; 91.7% susceptible, per the CLSI criteria) and colistin (MIC50/90, 1/2 g/ml; 98.9% susceptible, per the CLSI criteria; data not shown). Moreover, ceftazidime-avibactam inhibited 71.8 and 87.9% of the P. aeruginosa strains nonsusceptible to ceftazidime, meropenem, and piperacillin-tazobactam at MICs of 8 and 16 g/ml, respectively (Table 1). Ceftazidime-avibactam was also active against MDR (MIC50/90, 4/16 g/ml; 81.0% susceptible) and XDR (MIC50/90, 8/32 g/ml; 73.7% susceptible) P. aeruginosa (Tables 1 and 2). Besides ceftazidime-avibactam, only colistin (MIC50/90, 1/2 g/ml for both subsets; 98.8 to 99.0% susceptible, per the CLSI criteria) and amikacin (MIC50/90, 4 to 8/32 g/ml; 83.7 to 87.9% susceptible, per the CLSI criteria) exhibited good activity against MDR and XDR isolates of P. aeruginosa (Table 2). Ceftazidime is a well-established cephalosporin with an excellent safety profile and broad-spectrum activity against Gram-negative organisms, including P. aeruginosa (18). Avibactam is a novel non- -lactam -lactamase inhibitor that protects -lactams from hydrolysis by serine -lactamases (7, 19), including AmpC, which represents an important resistance mechanism among P. aeruginosa (3, 4, 20). The results of the present study indicate that avibactam restores ceftazidime wild-type activity against most ceftazidime-nonsusceptible P. aeruginosa strains, consistent with the results of a similar study of European isolates of P. aeruginosa (21). Ceftazidime-avibactam (MIC50/90, 2/4 g/ ml; 96.9% susceptible at 8 g/ml) showed greater anti-P. aeruginosa activity than ceftazidime (MIC50/90, 2/32 g/ml; 83.8% susceptible) and inhibited 80.9% of the ceftazidime-nonsusceptible strains at 8 g/ml. Moreover, ceftazidime-avibactam was active against P. aeruginosa strains exhibiting nonsusceptibility to meropenem (MIC50/90, 4/16 g/ml; 86.5% susceptible) or piperacillintazobactam (MIC50/90, 4/16 g/ml; 85.8% susceptible), and against many strains nonsusceptible to ceftazidime, meropenem, and piperacillin-tazobactam (MIC50/90, 8/32 g/ml; 71.8% susceptible). Mushtaq, Warner, and Livermore (9) evaluated the in vitro activities of ceftazidime-avibactam and various antipseudomonal -lactams against 26 AmpC mutant P. aeruginosa strains, includ- Organism (no. tested)a 0.25 0.5 1 2 4 8 16 32 32 50% 90% All isolates (3,902) 60 (1.5) 194 (6.5) 1,523 (45.5) 1,217 (76.7) 563 (91.2) 223 (96.9b) 74 (98.8) 23 (99.4) 25 (100.0) 2 4 CAZ-NS (634) 1 (0.2) 41 (6.6) 149 (30.1) 181 (58.7) 141 (80.9b) 73 (92.4) 23 (96.1) 25 (100.0) 4 16 MEM-NS (702) 8 (1.1) 63 (10.1) 172 (34.6) 218 (65.7) 146 (86.5b) 54 (94.2) 18 (96.7) 23 (100.0) 4 16 P-T-NS (837) 4 (0.5) 62 (7.9) 189 (30.5) 267 (62.4) 196 (85.8b) 72 (94.4) 22 (97.0) 25 (100.0) 4 16 MER-NS, CAZ-NS, and P-T-NS (330) 1 (0.3) 4 (1.5) 45 (15.2) 87 (45.1) 100 (71.8b) 53 (87.9) 17 (93.0) 23 (100.0) 8 32 MDR (580) 1 (0.2) 3 (0.7) 31 (6.0) 113 (25.5) 174 (55.5) 148 (81.0b) 64 (92.1) 21 (95.7) 25 (100.0) 4 16 XDR (338) 1 (0.3) 8 (2.7) 51 (17.8) 88 (43.8) 101 (73.7b) 46 (87.3) 18 (92.6) 25 (100.0) 8 32 a CAZ, ceftazidime; MEM, meropenem; P-T, piperacillin-tazobactam; NS, nonsusceptible; MDR, multidrug resistant; XDR, extensively drug-resistant. b Percent susceptible according to the U.S. FDA breakpoint criteria (11). June 2015 Volume 59 Number 6 aac.asm.org 3657Antimicrobial Agents and Chemotherapy on M ay 28, 2015 by P E N N S T A T E U N IV http://aac.asm .org/ D ow nloaded from ing strains with derepressed AmpC associated with a lack of OprD; 22 of 26 strains had ceftazidime MICs of 64 g/ml. The results showed that avibactam negated most AmpC-mediated resistance in P. aeruginosa, reducing ceftazidime MICs to the wild-type susceptible range, according to the current CLSI, U.S. Food and Drug Administration, and EUCAST susceptible breakpoint of 8 g/ml (9). Ceftazidime-avibactam activity against P. aeruginosa resistant to ceftazidime, piperacillin-tazobactam, or meropenem (as well as MDR strains) has also been reported by Walkty et al. (22). These investigators evaluated 470 clinical isolates from 15 tertiary care medical centers in Canada and showed that the addition of avibactam to ceftazidime lowered the ceftazidime MIC by 2- to 4-fold, and 66.1% of the ceftazidime-resistant strains exhibited ceftazidime-avibactam MICs of 8 g/ml (22). In summary, the results of this study corroborate and expand those results of other investigations by testing a large collection (3,902) of contemporary clinical strains. The use of avibactam, a broad-spectrum -lactamase inhibitor, in combination with a well-known -lactam, such as ceftazidime, could become a valuable addition to the limited armamentarium currently available to treat serious P. aeruginosa infections.
ACKNOWLEDGMENTS
We thank all participants of the International Network for Optimal Resistance Monitoring (INFORM) program for providing bacterial isolates. This study was supported by Cerexa, Inc., a wholly owned subsidiary of Forest Laboratories, Inc. Forest Laboratories, Inc., was involved in the design and decision to present these results. Forest Laboratories, Inc., had no involvement in the collection, analysis, and interpretation of data. JMI Laboratories, Inc., also received research and educational grants in 2012 to 2014 from Achaogen, Actelion, Affinium, the American Proficiency Institute (API), AmpliPhi Biosciences, Anacor, Astellas, AstraZeneca, Basilea, BioVersys, Cardeas, Cempra, Cubist, Daiichi Sankyo, Dipexium, Durata, Exela, Fedora, Furiex, Genentech, GlaxoSmithKline, Janssen, Johnson & Johnson, Medpace, Meiji Seika Kaisha, Melinta, Merck, MethylGene, Nabriva, Nanosphere, Novartis, Pfizer, Polyphor, Rempex, Roche, Seachaid, Shionogi, Synthes, The Medicines Co., Theravance, Thermo Fisher, Antimicrobial agenta 50% 90% Range CLSI EUCAST All isolates (n 3,902) Ceftazidime-avibactam 2 4 0.03 to 32 96.9/0.0/3.1c 96.9/0.0/3.1d Ceftazidime 2 32 0.06 to 32 83.8/3.6/12.6 83.8/0.0/16.2 Cefepime 2 16 0.5 to 16 83.6/8.4/8.0 83.6/0.0/16.4 Piperacillin-tazobactam 8 64 0.5 to 64 78.5/9.1/12.4 78.5/0.0/21.5 Meropenem 0.5 8 0.06 to 8 81.9/5.8/12.3 81.9/11.9/6.2 Ciprofloxacin 0.12 4 0.03 to 4 77.0/5.1/17.9 71.8/5.2/23.0 Levofloxacin 0.5 4 0.12 to 4 74.9/6.4/18.7 66.5/8.4/25.1 Gentamicin 1 8 1 to 8 88.9/3.2/7.9 88.9/0.0/11.1 Amikacin 2 8 0.25 to 32 97.4/1.1/1.5 94.0/3.4/2.6 Colistin 1 2 0.12 to 8 99.3/0.6/0.1 99.9/0.0/0.1 MDR strains (n 580) Ceftazidime-avibactam 4 16 0.25 to 32 81.0/0.0/19.0c 81.0/0.0/19.0d Ceftazidime 32 32 1 to 32 22.4/16.0/61.6 22.4/0.0/77.6 Cefepime 16 16 1 to 16 22.9/34.9/42.2 22.9/0.0/77.1 Piperacillin-tazobactam 64 64 1 to 64 8.6/30.5/60.9 8.6/0.0/91.4 Meropenem 8 8 0.06 to 8 21.6/16.3/62.1 21.6/43.9/34.5 Ciprofloxacin 4 4 0.03 to 4 20.9/10.1/69.0 13.6/7.3/79.1 Levofloxacin 4 4 0.12 to 4 15.0/13.3/71.7 9.8/5.2/85.0 Gentamicin 4 8 1 to 8 51.4/9.5/39.1 51.4/0.0/48.6 Amikacin 4 32 0.25 to 32 87.9/5.0/7.1 76.6/11.3/12.1 Colistin 1 2 0.25 to 8 99.0/0.7/0.3 99.7/0.0/0.3 XDR strains (n 338) Ceftazidime-avibactam 8 32 0.5 to 32 73.7/0.0/26.3c 73.7/0.0/26.3d Ceftazidime 32 32 1 to 32 10.1/17.1/72.8 10.1/0.0/89.9 Cefepime 16 16 4 to 16 11.8/32.3/55.9 11.8/0.0/88.2 Piperacillin-tazobactam 64 64 8 to 64 2.7/23.6/73.7 2.7/0.0/97.3 Meropenem 8 8 0.12 to 8 7.1/14.8/78.1 7.1/47.3/45.6 Ciprofloxacin 4 4 0.12 to 4 7.7/9.5/82.8 2.7/5.0/92.3 Levofloxacin 4 4 0.25 to 4 3.6/11.2/85.2 2.1/1.4/96.5 Gentamicin 8 8 1 to 8 37.0/10.0/53.0 37.0/0.0/63.0 Amikacin 8 32 0.25 to 32 83.7/6.5/9.8 69.8/13.9/16.3 Colistin 1 2 0.25 to 8 98.8/0.9/0.3 99.7/0.0/0.3 a MDR, multidrug resistant; XDR, extensively drug resistant (17). b S, susceptible; I, intermediate; R, resistant, according to criteria as published by the CLSI (15) and EUCAST (16). c U.S. FDA breakpoint criteria were applied (11). d EUCAST susceptibility criteria for ceftazidime alone were applied for comparison purposes only (16). 3658 aac.asm.org June 2015 Volume 59 Number 6Antimicrobial Agents and Chemotherapy on M ay 28, 2015 by P E N N S T A T E U N IV http://aac.asm .org/ D ow nloaded from VenatoRx, Vertex, Waterloo, and Wockhardt. Some JMI employees are advisors/consultants for Astellas, Cubist, Pfizer, Cempra, Cerexa-Forest, and Theravance. We declare no other conflicts of interest.
Less ...
 
Article Images (0)